Table 1.
Patient characteristics
| Characteristic | Low donor‐derived cell‐free DNA (dd‐cfDNA) (<0.5) | High dd‐cfDNA (≥0.5) | P value | |
|---|---|---|---|---|
| Age (y) | N | 37 | 42 | .028 |
| Mean (SD) | 49.8 (10.46) | 44.1 (12.14) | ||
| Median (Q1, Q3) | 48 (44, 56) | 43 (36, 55) | ||
| Min, Max | 29, 77 | 23, 69 | ||
| Height (cm) | N | 13 | 17 | .952 |
| Mean (SD) | 165.8 (32.37) | 165.2 (27.78) | ||
| Median (Q1, Q3) | 175 (169, 188) | 172.7 (160, 178) | ||
| Min, Max | 62, 188 | 66, 189 | ||
| Weight (kg) | N | 13 | 17 | .279 |
| Mean (SD) | 96.7 (27.31) | 86.3 (24.06) | ||
| Median (Q1, Q3) | 94.3 (77, 110) | 81 (72, 92) | ||
| Min, Max | 64, 155 | 55, 160 | ||
| Estimated glomerular filtration rate at diagnosis of TCMR1A (mL/min/1.73 m2) | N | 37 | 42 | .340 |
| Mean (SD) | 46.3 (15.18) | 49.7 (14.53) | ||
| Median (Q1, Q3) | 48 (33, 57) | 49 (40, 59) | ||
| Min, Max | 9, 79 | 11, 84 | ||
| Race | White | 29 (78.4%) | 31 (73.8%) | .428 |
| African American | 7 (18.9%) | 11 (26.2%) | ||
| Asian | 1 (2.7%) | 0 | ||
| Gender | Male | 22 (59.5%) | 17 (40.5%) | .117 |
| Female | 15 (40.5%) | 25 (59.5%) | ||
| Kidney disease | Congenital or familial disorders | 1 (7.7%) | 1 (6.7%) | .945 |
| FSGS | 2 (15.4%) | 1 (6.7%) | ||
| Glomerular disease | 1 (7.7%) | 2 (13.3%) | ||
| Hypertensive nephrosclerosis | 4 (30.8%) | 3 (20.0%) | ||
| Neoplasms | 0 | 1 (6.7%) | ||
| Other | 0 | 1 (6.7%) | ||
| PKD | 0 | 2 (13.3%) | ||
| Tubular and interstitial disease | 1 (7.7%) | 0 | ||
| Type II diabetes | 1 (7.7%) | 1 (6.7%) | ||
| Biopsy | For cause | 17 (45.9%) | 21 (50%) | .647 |
| Protocol | 20 (54.1%) | 21 (50%) |
Abbreviations: FSGS, focal segmental glomerulosclerosis; PKD, polycystic kidney disease; TCMR, T cell–mediated rejection.